A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants

Official title

A Phase 1, Open-Label, Randomized, Single-Dose, Three-Treatment, Three-Period, Six-Sequence Crossover Pharmacokinetic Study to Evaluate the Bioequivalence of Two Casdatifan (AB521) Tablet Strengths and Food Effect in Healthy Adult Participants

Overview

The purpose of this study is to compare the single-dose pharmacokinetics (PK) of casdatifan 100 mg versus four 25 mg tablets under fasting conditions in healthy adult participants, and to evaluate the effect of food on the single-dose PK of casdatifan 100 mg administered as four 25 mg tablets in healthy adult participants.

Interventions

• Drug Casdatifan
  Administered as specified in the treatment arm

Primary outcome measures

• Maximum observed concentration for casdatifan [Time frame: Up to 168 hours post each dose]
• Area under the concentration-time curve for casdatifan [Time frame: Up to 168 hours post each dose]

Secondary outcome measures (8)

• Time to reach Cmax (Tmax) for casdatifan [Time frame: Up to 168 hours post each dose]
• Lag time (Tlag) for casdatifan [Time frame: Up to 168 hours post each dose]
• Apparent first-order terminal elimination rate constant (Kel) for casdatifan [Time frame: Up to 168 hours post each dose]
• Percent of AUC0-inf extrapolated for casdatifan [Time frame: Up to 168 hours post each dose]
• Apparent first-order terminal elimination half-life (t½) for casdatifan [Time frame: Up to 168 hours post each dose]
• Apparent total clearance after extravascular (oral) administration (CL/F) for casdatifan [Time frame: Up to 168 hours post each dose]
• Apparent total clearance after extravascular (oral) administration (Vz/F) for casdatifan [Time frame: Up to 168 hours post each dose]
• Number of participants experiencing Adverse Events (AEs) [Time frame: Up to 43 days]

Eligibility criteria

Inclusion criteria

• Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on participant self-reporting.
• BMI ≥ 18.0 and ≤ 32.0 kg/m2 and body weight ≥ 45 kg at the screening visit.
• Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, standard vital signs, and ECGs, as deemed by the PI or designee.
• Able to swallow multiple tablets.
• Has adequate peripheral venous access.

Exclusion criteria

• Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
• History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
• History of asthma or chronic obstructive pulmonary disease (including childhood), clinically significant food allergies or anaphylaxis, as deemed by PI or designee.
• Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of asymptomatic gallstones).
• Seizure (excluding simple febrile seizure), epilepsy, severe head injury, multiple sclerosis, or other known neurological conditions which the PI or designee considers to be clinically significant.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation

Randomized

Model

Crossover

Masking

Open label

Primary purpose

Basic science

Study locations

United States · 1 center

• Research Site — Tempe

Identifiers

NCT: NCT07641881 · ARC-30

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗